Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

(2021) Amani Makkouk et al.   Journal for ImmunoTherapy of Cancer

Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab

(2020) Lionel Rougé et al.   SCIENCE

Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15

(2019) Yuhui Chen et al.   CLINICAL CANCER RESEARCH

Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells

(2019) Biagio Di Lorenzo et al.   Cancer Immunology Research

Mechanisms of resistance to CAR T cell therapy

(2019) Nirali N. Shah et al.   Nature Reviews Clinical Oncology

CAR-T efficacy: is conditioning the key?

(2019) Sattva S. Neelapu   BLOOD

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

(2019) Cesar Sommer et al.   MOLECULAR THERAPY

Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation

(2019) Alice Bertaina et al.   Frontiers in Immunology

Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies

(2019) Zsolt Sebestyen et al.   NATURE REVIEWS DRUG DISCOVERY

Engineering γδT cells limits tonic signaling associated with chimeric antigen receptors

(2019) Jonathan Fisher et al.   Science Signaling

An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer

(2019) Yin Wu et al.   Science Translational Medicine

Off the shelf T cell therapies for hematologic malignancies

(2018) Bruce J. McCreedy et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells associate with clinical outcomes in NHL

(2018) John Rossi et al.   BLOOD

Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation

(2018) Anna Capsomidis et al.   MOLECULAR THERAPY

Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia

(2018) Joseph A. Fraietta et al.   NATURE MEDICINE

Functional Plasticity of Gamma Delta T Cells and Breast Tumor Targets in Hypoxia

(2018) Gabrielle M. Siegers et al.   Frontiers in Immunology

Cell Therapy Products: Focus on Issues with Manufacturing and Quality Control of Chimeric Antigen Receptor T-cell therapies

(2018) Jim E. Eyles et al.   JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY

TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach.

(2018) David Edward Gilham et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic CAR-T Cells: More than Ease of Access?

(2018) Charlotte Graham et al.   Cells

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Clonal selection in the human Vδ1 T cell repertoire indicates γδ TCR-dependent adaptive immune surveillance

(2017) Martin S. Davey et al.   Nature Communications

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

Dynamic Analysis of Human Natural Killer Cell Response at Single-Cell Resolution in B-Cell Non-Hodgkin Lymphoma

(2017) Saheli Sarkar et al.   Frontiers in Immunology

Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response

(2017) Qiong Xue et al.   Journal for ImmunoTherapy of Cancer

Delta One T Cells for Immunotherapy of Chronic Lymphocytic Leukemia: Clinical-Grade Expansion/Differentiation and Preclinical Proof of Concept

(2016) A. R. Almeida et al.   CLINICAL CANCER RESEARCH

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

(2016) N. H. Fowler et al.   HAEMATOLOGICA

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

(2016) N. H. Fowler et al.   HAEMATOLOGICA

Gamma Delta T Cell Reconstitution Is Associated with Fewer Infections and Improved Event-Free Survival after Hematopoietic Stem Cell Transplantation for Pediatric Leukemia

(2015) Ross Perko et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

(2015) D Sommermeyer et al.   LEUKEMIA

The prognostic landscape of genes and infiltrating immune cells across human cancers

(2015) Andrew J Gentles et al.   NATURE MEDICINE

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys

(2015) Eric J. Smith et al.   Scientific Reports

Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells

(2015) M. J. Frigault et al.   Cancer Immunology Research

Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15

(2014) Y. Xu et al.   BLOOD

Cytotoxic and Regulatory Properties of Circulating Vδ1+ γδ T Cells: A New Player on the Cell Therapy Field?

(2014) Gabrielle M Siegers et al.   MOLECULAR THERAPY

Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice

(2014) A. J. Murphy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical Applications of Gamma Delta T Cells with Multivalent Immunity

(2014) Drew C. Deniger et al.   Frontiers in Immunology

Tumor-Infiltrating γδ T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programing in the Tumor Microenvironment

(2014) Elena Lo Presti et al.   Frontiers in Immunology

Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry

(2012) Zhili Zheng et al.   Journal of Translational Medicine

TCR Nanoclusters as the Framework for Transmission of Conformational Changes and Cooperativity

(2012) Raquel Blanco et al.   Frontiers in Immunology

The predictive significance of CD20 expression in B-cell lymphomas

(2011) Veronika Prevodnik et al.   Diagnostic Pathology

Targeting    T Lymphocytes for Cancer Immunotherapy: From Novel Mechanistic Insight to Clinical Application

(2010) A. Q. Gomes et al.   CANCER RESEARCH

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Establishment of a novel CD20 negative mature B-cell line, WILL2, from a CD20 positive diffuse large B-cell lymphoma patient treated with rituximab

(2009) Takashi Sonoki et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20

(2008) D. Dayde et al.   BLOOD

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH